Full Breakdown
Novo Nordisk Faces Class Action Lawsuit Over Victoza Monopoly Allegations
1/25/2026, 7:56:58 PM
Allegations of Patent Misuse and Market Manipulation
Danish pharmaceutical company Novo Nordisk is facing a class action lawsuit filed in the U.S. District Court for the Eastern District of New York. The lawsuit, initiated by South Carolina-based wholesaler Smith Drug, accuses Novo Nordisk of employing a "pay-for-delay" scheme in collaboration with Teva Pharmaceuticals to unlawfully maintain a monopoly on its diabetes medication, Victoza. The complaint alleges that this agreement delayed the entry of generic versions of Victoza into the market, which could have been available as early as 2023, instead of the actual launch in 2024.
The lawsuit claims that Novo Nordisk's actions have caused significant financial harm to consumers who purchased Victoza, which generated over $5 billion in sales in the U.S. in 2018. The company’s second-generation GLP-1 drug, Ozempic, has since become a major revenue driver, contributing to Novo's status as one of the most valuable companies in Europe.
Background on Victoza and Generic Competition
Victoza, approved by the U.S. Food and Drug Administration in 2010, is a first-generation GLP-1 receptor agonist used for managing diabetes. The lawsuit highlights a 2019 settlement between Novo and Teva, which allegedly involved Novo paying Teva to delay the launch of a generic version of Victoza. This agreement is at the heart of the allegations, as it purportedly violates antitrust laws by preventing competition in the diabetes medication market.
Market Context and Financial Implications
As Novo Nordisk navigates this legal challenge, its stock performance remains a focal point for investors. The company's Class B shares recently closed higher, buoyed by strong early demand for its new weight-loss drug, Wegovy. Analysts have noted that much of Novo's profitability is tied to its obesity drug franchise, which is seen as a critical growth area amid the ongoing litigation regarding Victoza.
Official Statements & Responses
Novo Nordisk has declined to comment on the lawsuit, maintaining a position of silence as the case unfolds. Smith Drug, representing the proposed class of Victoza purchasers, is seeking unspecified monetary damages. The legal proceedings will likely draw attention to the broader implications of patent manipulation in the pharmaceutical industry.
Criticism & Opposition
Critics of Novo Nordisk's practices argue that the alleged "pay-for-delay" schemes undermine market competition and keep drug prices artificially high, impacting patients who rely on affordable medication options. The lawsuit reflects growing scrutiny of pharmaceutical companies and their pricing strategies, particularly in the context of essential medications like those for diabetes.
What's Next
The upcoming court proceedings will be closely monitored, as they may set a precedent for how pharmaceutical companies manage patent rights and competition. Additionally, Novo is expected to release its fourth-quarter 2025 results on February 4, which will provide further insights into the company's financial health and its strategies for addressing the ongoing litigation and potential generic competition.
